Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Primary drug resistance to anti-tuberculosis drugs in major towns of Amhara region, Ethiopia
APMIS, Volume 120, No. 6, Year 2012
Notification
URL copied to clipboard!
Description
Drug resistance is a major obstacle to effective TB control program performance. In this study, we assessed the prevalence of primary drug resistance in Mycobacterium tuberculosis (Mtb) isolates in Amhara Region, Ethiopia. A total of 112 Mtb isolates from cases with newly diagnosed pulmonary TB were subjected to drug susceptibility testing (DST) in a cross-sectional study. Isolates were tested for sensitivity to isoniazid, rifampicin, ethambutol, and streptomycin using the MGIT 960 protocol. A total of 93 Mtb isolates yielded valid DST results and 28 (30.1%) were resistant to one or more of first line anti-TB drugs. One isolate (1.0%) was multi-drug resistant (MDR), five (5.4%) were classified as poly-resistant and 22 showed single drug resistance to either streptomycin (n=19) or isoniazid (n=3). Isolates from HIV-positive patients were more likely to be resistant to at least one of the four anti-TB drugs compared with HIV-negative individuals (odds ratio 2.76, 95% confidence interval 1.06-7.22; p=0.03). The study showed a high prevalence of primary drug resistance. Even though the prevalence of MDR was low, conditions that can contribute to the development of MDR are increasing. Therefore, regular monitoring of drug resistance and enhanced implementation of TB/HIV collaborative activities in the study region are imperative. © 2012 The Authors. APMIS © 2012 APMIS.
Authors & Co-Authors
Yimer, Solomon Abebe
Norway, Oslo
Folkehelseinstituttet
Norway, Oslo
Medisinske Fakultet
Ethiopia, Bahar Dar
Amhara Regional Health Bureau
Agonafir, Mulualem
Ethiopia, Addis Ababa
Ethiopian Public Health Institute
Derese, Yohannes
Ethiopia, Addis Ababa
Armauer Hansen Research Institute
Sani, Yusuf
Ethiopia, Addis Ababa
Armauer Hansen Research Institute
Bjune, Gunnar Aksel
Norway, Oslo
Medisinske Fakultet
Holm-Hansen, Carol
Norway, Oslo
Folkehelseinstituttet
Statistics
Citations: 35
Authors: 6
Affiliations: 5
Identifiers
Doi:
10.1111/j.1600-0463.2011.02861.x
ISSN:
09034641
e-ISSN:
16000463
Research Areas
Infectious Diseases
Study Design
Cross Sectional Study
Case-Control Study
Study Approach
Quantitative
Study Locations
Ethiopia